Sosei Group ( (JP:4565) ) has provided an update.
Nxera Pharma’s partner, Tempero Bio, has initiated a Phase 2 trial for TMP-301, a drug aimed at treating alcohol use disorder. This development marks a significant step forward for Nxera’s NxWave™ discovery platform, showcasing its capability to produce innovative drug candidates. The collaboration with Tempero Bio, which holds exclusive global rights to Nxera’s mGluR5 NAM portfolio, is expected to advance the clinical development of treatments for substance use disorders. While no milestone payment is due at this stage, Nxera stands to benefit from future success-based payments and royalties, highlighting the strategic importance of this partnership.
More about Sosei Group
Nxera Pharma is a technology-driven biopharmaceutical company focused on developing new specialty medicines to address unmet medical needs in Japan and globally. The company has a robust pipeline of over 30 active programs targeting areas such as neurology, gastrointestinal and immunology, metabolic disorders, and rare diseases. Utilizing its proprietary GPCR-targeted structure-based drug discovery platform, NxWave™, Nxera aims to deliver innovative candidates that are either best-in-class or first-in-class. The company operates in key locations including Tokyo, Osaka, London, Cambridge, Basel, and Seoul, and is listed on the Tokyo Stock Exchange.
YTD Price Performance: -6.67%
Average Trading Volume: 300
Technical Sentiment Signal: Buy
Current Market Cap: $540M
See more data about 4565 stock on TipRanks’ Stock Analysis page.